Vistagen Therapeutics Inc
NASDAQ:VTGN

  • LAST PRICE
    2.6300
  • TODAY'S CHANGE (%)
    -0.1000 (-3.6630%)
  • Bid / Lots
    2.5600/ 2
  • Ask / Lots
    2.6400/ 2
  • Open / Previous Close
    2.7100 / 2.7300
  • Day Range
    2.5800
    2.7190
  • 52 Week Range
    2.5800
    5.8600
  • Volume
    356,684

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
VTGN
Vistagen Therapeutics Inc
73.2M
-2.0x
---
OVID
Ovid Therapeutics Inc
75.2M
-2.3x
---
AVTE
Aerovate Therapeutics Inc
73.0M
-0.8x
---
PDSB
PDS Biotechnology Corp
74.0M
-1.6x
---
BCAB
Bioatla Inc
75.4M
-0.9x
---
CMRX
Chimerix Inc
77.3M
-0.9x
---
As of 2024-11-17

Company Information

Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.

Contact Information

Headquarters
343 ALLERTON AVENUESOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-577-3600
Fax
---

Executives

Independent Chairman of the Board
Margaret Fitzpatrick
Chief Executive Officer, Director
Shawn Singh
Chief Financial Officer
Cynthia Anderson
Chief Operating Officer
Joshua Prince
Senior Vice President - Investor Relations
Mark Mcpartland

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$73.2M
Revenue (TTM)
$875.7K
Shares Outstanding
27.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.84
EPS
$-1.30
Book Value
$4.23
P/E Ratio
-2.0x
Price/Sales (TTM)
83.6
Price/Cash Flow (TTM)
---
Operating Margin
-5,207.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.